Overview

Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer

Status:
Recruiting

Trial end date:
2025-08-31

Target enrollment:

Participant gender:

Summary

This is a multi-center, stratified and single-blinded Phase 2 study of neoadjuvant immunotherapy in combination with the antiGDF15 antibody visugromab (CTL-002) for the treatment of subjects with MIBC set to undergo radical Cystectomy (RC) who cannot receive or refuse to receive cisplatin-based chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

CatalYm GmbH

Treatments:

Nivolumab